The crystal structures of human α-thrombin complexed with active site- directed diamino benzo[b]thiophene derivatives: A binding mode for a structurally novel class of inhibitors

Protein Science

Volumn 9, Issue 1, 2000, Pages 29-36

  Chirgadze, N Y ^a   Sall, D J ^a   Briggs, S L ^a   Clawson, D K ^a   Zhang, M ^a   Smith, G F ^a   Schevitz, R W ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Benzo b thiophene; Human thrombin; Nonpeptidyl inhibitor; Structure based drug design; X ray crystallography

Indexed keywords

THIOPHENE DERIVATIVE; THROMBIN;

ARTICLE; CRYSTAL STRUCTURE; DRUG DESIGN; HYDROGEN BOND; PRIORITY JOURNAL; PROTEIN STRUCTURE; X RAY CRYSTALLOGRAPHY;

EID: 0033985723     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1110/ps.9.1.29     Document Type: Article

References (36)

1. Banner DW, Hadvary P. 1991. Crystallographic analysis at 3.0 Å resolution of the binding to human thrombin of four active site-directed inhibitors. J Biol Chem 226:20085-20093.
2. Barnett HJM. 1991. Thrombotic processes in cerebrovascular disease. J Biol Chem 226:1301-1315.
3. Berliner LT. 1992. Thrombin structure and function. New York: Plenum Press.
4. Bode W, Mayr I, Baumann U, Huber R, Stone S, Hoffsteenge J. 1989. The refined 1.9 A crystal structure of human α-thrombin: Interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J 8:3467-3475.
5. Bode W, Turk D, Karshikov A. 1992. The refined 1.9 Å X-ray crystal structure of D-Phe-Pro-Arg chlormethylkethone-inhibited human α-thrombin: Structure analysis, overall structure, electrostatic properties. Detailed active site geometry and structure-function relationships. Protein Sci 1:426-471.
6. Brünger AT. 1992. X-PLOR, version 3.1: A system for X-ray crystallography and NMR. New Haven, Connecticut: Yale University Press.
7. Chirgadze NY, Clawson DK, Gesellchen PD, Hermann RB, Kaiser RE Jr, Olkowski JL, Sall DJ, Schevitz RW, Smith GF, Shuman RT, et al. 1992. The X-ray structure at 2.2 Å of a ternary complex containing human α-thrombin, a hirudin peptide (54-65) and an active site inhibitor. American Crystallographic Association meeting, Pittsburgh, Pennsylvania, August 9-14, Vol. 20. p 116.
8. Chirgadze NY, Sall DJ, Klimkowski VJ, Clawson DK, Briggs SL, Hermann R, Smith GF, Gifford-Moore DS, Wery J-P. 1997. The crystal structure of human α-thrombin complexed with LY178550, a non-peptidyl, active-site directed inhibitor. Protein Sci 6:1412-1417.
9. Chirgadze NY, Wiley MR, Schacht AL, Shuman RT, Smith GF, Sall DL, Clawson DK, Hermann RB, Schevitz RW, Jones ND, et al. 1996. Structure based design of human α-thrombin active site inhibitors: Interaction in the insertion loop region. Experimental and computational approaches to structure-based drug design, Erice, Italy, May 9-19. p 420.
10. Colman RW, Cook JJ, Niewiarowski S. 1994a. Mechanisms of platelet aggregation. In: Colman RW, Hirsh J, Marder, VJ, Salzman EW, eds. Hemostasis and thrombosis: Basic principles and clinical practice, 3rd ed. Philadelphia, Pennsylvania: J.B. Lippincott Co. pp 508-523.
11. Colman RW, Marder VJ, Salzman EW, Hirsh J. 1994b. Overview of hemostasis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and thrombosis: Basic principles and clinical practice, 3rd ed. Philadelphia, Pennsylvania: J.B. Lippincott Co. pp 3-18.
12. Dougherty D. 1996 Cation-π interactions in chemistry and biology: A new view of benzene, Phe, Tyr, and Trp. Science 271:163-167.
13. Edmunds JJ, Rapundalo ST. 1996. Thrombin and factor Xa inhibition. Annu Rep Med Chem 31:51-60.
14. Engh RA, Huber R. 1991. Accurate bond and angle parameters for X-ray protein structure refinement. Acta Crystallogr A 47:392-400.
15. Hartley BS, Shotton DM. 1971. In Boyer PD, ed. The enzymes, vol. 3. New York: Academic Press. pp 323-373.
16. Hirsh J, Salzman EW, Marder VJ, Colman RW. 1987. Overview of the thrombotic process and its therapy. In: Colman RW, Hirsh J, Marder VJ, Salzman EW. eds. Hemostasis and thrombosis, basic principles and clinical practice, 2nd ed. Philadelphia, Pennsylvania: J.B. Lippincott Co. pp 1063-1072.
17. Iwanowicz EJ, Lau WF, Lin J, Roberts DGM, Seller S. 1994. Retro-binding tripeptide thrombin active site inhibitors: Discovery, synthesis, and molecular modeling. J Med Chem 37:2122-2124.
18. Kaiser B. 1998. Thrombin and factor Xa inhibitors. Drugs Future 23:423-436.
19. Kimball SD. 1999. Oral thrombin inhibitors: Challenges and progress. Handb Exp Pharmacol (Antithrombot) 132:367-396.
20. Machovich R. 1984. Thrombin and hemostasis. In: Machovich R, ed. The thrombin, vol. 1. Boca Raton, Florida: CRC Press, Inc. pp 1-22.
21. Maryanoff BE, Qiu X, Padmanabhan KP, Tulinsky A, Almond HR Jr, Andrade-Gordon P, Greco MN, Kauffman JA, Nicolaou KC, Liu A, et al. 1993. Molecular basis for the inhibition of human α-thrombin by the macrocyclic peptide cyclotheonamide A. Proc Natl Acad Sci USA 90:8048-8052.
22. Menear K. 1998. Progress towards the discovery of orally active thrombin inhibitors. Curr Med Chem 5:457-468.
23. Otwinowski Z. 1993. Oscillation data reduction program. In: Proceedings of the CCP4 study weekend: Data collection and processing. UK: SERC Daresbury Laboratory. pp 56-62.
24. Otwinowski Z, Minor W. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276:307-326.
25. Sall DL, Bastian JA, Briggs SL, Buben JA. Chirgadze NY, Clawson DK, Denney ML, Giera DD, Gifford-Moore DS, Harper RW, et al. 1997. Dibasic benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors. 1. Determination of the serine protease selectivity, structure activity relationships, and binding orientation. J Med Chem 40:3489-3493.
26. Sall DJ, Bastian JA Chirgadze NY, Denney ML, Fisher MJ, Gifford-Moore DS, Harper RW, Klimkowski VJ, Kohn TJ, Lin HS, et al. 2000. Diamino benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors. 5. Structural modification of the C-3 side chain as a means to increase potency and selectivity. J Med Chem. Forthcoming.
27. 2) binding site. Bioorg Med Chem Lett 8:2527-2532.
28. Sanderson PEJ, Naylor-Olsen AM. 1998. Thrombin inhibitor design. Curr Med Chem 5:89-304.
29. Schacht AL, Wiley MR, Chirgadze NY, Clawson DK, Coffman WJ, Craft TJ, Gifford-Moore DS, Jones ND, Kurz KD, Moore R, et al. 1995. Tripeptide arginal thrombin inhibitors: Structure based modification of the proline (P2) residue. 34th National Organic Symposium, The College of William and Mary, Williamsburg, Virginia, June 11-15.
30. Shibata A. 1990. Diffraction data collection with R-AXIS II, an X-ray detecting system using imaging plate. Rigaku J 7:28-32.
31. Skrzypczak-Janjun E, Carpenos V, Ravichandran KG, Tulinsky A, Westbrook M, Maraganore JM. 1991. The structure of hirugen and hirulog 1 complexes of α-thrombin. J Mol Biol 221:1379-1393.
32. Smith GF, Craft TJ, Gifford-Moore DS, Coffman WJ, Kurz KD, Roberts E, Shuman RT, Sandusky GE, Jones ND, Chirgadze NY, Jackson CV. 1996. A family of arginal thrombin inhibitors related to Efegatran. Semin Thromb Hemost 22:173-183.
33. Smith GF, Gifford-Moore D, Craft TJ, Chirgadze N, Ruterbories KJ, Lindstrom TD, Satterwhite JH. 1997. Efegatran: A new cardiovascular anticoagulant. In: Pifarre R, ed. New anticoagulants for the cardiovascular patient. Philadelphia, Pennsylvania: Hanley & Belfus, Inc. pp 265-300.
34. Uzan A. 1998. Antithrombotic agents. Emerging Drags 3:189-208.
35. Want R, Liu L, Lai L, Tang Y. 1998. Structure-affinity relationship of thrombin inhibitors. Wuli Huaxue Xuebao 14:887-892.
36. Wiley MR, Fisher MJ. 1997. Small molecule thrombin inhibitors. Exp Opin Ther Patents 7:1265-1282.